Destiny Pharma plc("Destiny Pharma" or "the Company") Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients Brighton, United Kingdo.
Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: XF-73 Phase 2b data to be presented at ECCMID investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.